Cargando…

Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration

OBJECTIVES: This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascular age-related macular degeneration (nvAMD) and to define subgroups of poor responders. MATERIALS AND METHODS: A total of 235 treatment-naive eyes of 202 patients completed t...

Descripción completa

Detalles Bibliográficos
Autores principales: Barış, Mine Esen, Menteş, Jale, Afrashi, Filiz, Nalçaçı, Serhad, Akkın, Cezmi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Galenos Publishing 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610050/
https://www.ncbi.nlm.nih.gov/pubmed/33342194
http://dx.doi.org/10.4274/tjo.galenos.2020.38488
_version_ 1783605121355087872
author Barış, Mine Esen
Menteş, Jale
Afrashi, Filiz
Nalçaçı, Serhad
Akkın, Cezmi
author_facet Barış, Mine Esen
Menteş, Jale
Afrashi, Filiz
Nalçaçı, Serhad
Akkın, Cezmi
author_sort Barış, Mine Esen
collection PubMed
description OBJECTIVES: This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascular age-related macular degeneration (nvAMD) and to define subgroups of poor responders. MATERIALS AND METHODS: A total of 235 treatment-naive eyes of 202 patients completed this prospective study. Patients younger than 50 years of age and those with a contraindication for anti-VEGF therapy were excluded. All eyes were treated with IV ranibizumab. Poor response was defined as recurrence, persistence, or worsening despite treatment. Poor responders were classified into subgroups based on progression patterns. RESULTS: Of the 235 eyes, 78 (33.2%) showed poor response. Pigment epithelial detachment (PED) and occult choroidal neovascularization (CNV) were more common among poor responders (p<0.001) and 5 subgroups were identified. CONCLUSION: Poor response to anti-VEGF treatment is not uncommon and occult CNV and PED are frequently seen in these eyes. Various subgroups can be defined based on clinical features.
format Online
Article
Text
id pubmed-7610050
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Galenos Publishing
record_format MEDLINE/PubMed
spelling pubmed-76100502020-11-13 Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration Barış, Mine Esen Menteş, Jale Afrashi, Filiz Nalçaçı, Serhad Akkın, Cezmi Turk J Ophthalmol Original Article OBJECTIVES: This study aimed to determine the incidence of poor response to intravitreal (IV) anti-VEGF treatment in neovascular age-related macular degeneration (nvAMD) and to define subgroups of poor responders. MATERIALS AND METHODS: A total of 235 treatment-naive eyes of 202 patients completed this prospective study. Patients younger than 50 years of age and those with a contraindication for anti-VEGF therapy were excluded. All eyes were treated with IV ranibizumab. Poor response was defined as recurrence, persistence, or worsening despite treatment. Poor responders were classified into subgroups based on progression patterns. RESULTS: Of the 235 eyes, 78 (33.2%) showed poor response. Pigment epithelial detachment (PED) and occult choroidal neovascularization (CNV) were more common among poor responders (p<0.001) and 5 subgroups were identified. CONCLUSION: Poor response to anti-VEGF treatment is not uncommon and occult CNV and PED are frequently seen in these eyes. Various subgroups can be defined based on clinical features. Galenos Publishing 2020-10 2020-10-30 /pmc/articles/PMC7610050/ /pubmed/33342194 http://dx.doi.org/10.4274/tjo.galenos.2020.38488 Text en © Copyright 2020 by Turkish Ophthalmological Association | Turkish Journal of Ophthalmology, published by Galenos Publishing House. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Barış, Mine Esen
Menteş, Jale
Afrashi, Filiz
Nalçaçı, Serhad
Akkın, Cezmi
Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
title Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
title_full Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
title_fullStr Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
title_full_unstemmed Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
title_short Subgroups and Features of Poor Responders to Anti-Vascular Endothelial Growth Factor Treatment in Eyes with Neovascular Age-Related Macular Degeneration
title_sort subgroups and features of poor responders to anti-vascular endothelial growth factor treatment in eyes with neovascular age-related macular degeneration
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7610050/
https://www.ncbi.nlm.nih.gov/pubmed/33342194
http://dx.doi.org/10.4274/tjo.galenos.2020.38488
work_keys_str_mv AT barısmineesen subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration
AT mentesjale subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration
AT afrashifiliz subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration
AT nalcacıserhad subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration
AT akkıncezmi subgroupsandfeaturesofpoorresponderstoantivascularendothelialgrowthfactortreatmentineyeswithneovascularagerelatedmaculardegeneration